Arbutus Biopharma
ABUS
123 hedge funds and large institutions have $154M invested in Arbutus Biopharma in 2021 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 39 increasing their positions, 22 reducing their positions, and 19 closing their positions.
126% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 19
77% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 22
52% more call options, than puts
Call options by funds: $14.4M | Put options by funds: $9.51M
23% more funds holding
Funds holding: 100 → 123 (+23)
3% more capital invested
Capital invested by funds: $150M → $154M (+$4.65M)
5.85% less ownership
Funds ownership: 35.2% → 29.35% (-5.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$7.84M |
| 2 |
BC
Brookfield Corp
Toronto,
Ontario, Canada
|
+$4.63M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$3.47M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.07M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$8.66M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.84M |
| 3 |
SG Americas Securities
New York
|
-$2.24M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$2.13M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.7M |
ABUS Hedge Fund Activity: Q4 2021 in Review
123 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2021, worth a combined $154M — up 3.1% from $150M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new ABUS positions and 19 closed out — a net gain of 24 holders — while 39 added to existing stakes and 22 trimmed.
The largest buyer was Millennium Management, adding an estimated $7.84M. The largest seller was RTW Investments, cutting an estimated $8.66M.
- 123 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2021, up from 100 in Q3 2021.
- Funds reported $154M of Arbutus Biopharma stock for Q4 2021, up 3.1% quarter-over-quarter.
- 43 funds opened new Arbutus Biopharma positions in Q4 2021 and 19 closed out, a net change of +24 holders.
- The largest Arbutus Biopharma buyer in Q4 2021 was Millennium Management, an estimated $7.84M added.
- The largest Arbutus Biopharma seller in Q4 2021 was RTW Investments, an estimated $8.66M sold.
Based on aggregated 13F filings for Q4 2021.